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Abstract
Background: Heparin-induced thrombocytopenia is caused by antibodies (Abs) specific to platelet factor 4 (PF4)/
heparin complexes. In this study, we evaluated the rates of seroconversion of anti-PF4/heparin Ab between patients
with rheumatoid arthritis (RA) and with osteoarthritis (OA) who underwent total knee arthroplasty.
Methods: The subjects of this randomized controlled trial were 124 patients who underwent total knee
arthroplasty (TKA) and received edoxaban with or without a foot pump as thromboprophylaxis. We measured
anti-PF4/heparin Abs before and 10 days after surgery, as well as preoperative PF4, using commercially available
ELISAs. We also used the database of J-PSVT, a hospital-based, prospective cohort study designed to document the
effectiveness of thromboprophylactic agents during arthroplasty.
Results: The rates of seroconversion to anti-PF4/heparin Ab were lower in RA patients (4.0 %) than in OA patients
(25.5 %). The anti-PF4/heparin IgG optical density (OD) values did not differ before and after surgery in RA patients.
In contrast, there was a significant increase in anti-PF4/heparin IgG OD values in OA patients after TKA. In the J-PSVT
data, the postoperative seroconversion rates of anti-PF4/heparin Ab were lower in RA patients (10.4 %) than in OA
patients (21.8 %) who received fondaparinux. The titers of anti-CCP Ab were significantly lower in RA patients with
postoperative ant-PF4/heparin Ab compared with those without postoperative ant-PF4/heparin Ab There was no
significant difference in preoperative PF4 levels between RA patients and OA patients. The heparin-binding affinity of
the circulating PF4 was similar between RA patients and OA patients; however, the IgG fractions isolated from the sera
of RA patients contained PF4 more frequently (69.2 %) than those from OA patients (10.2 %).
Conclusions: Our results showed a reduced likelihood of postoperative anti-PF/heparin Ab production in RA patients
compared with OA patients. This suggests that the mechanisms underlying the anti-PF4 immune response in RA
patients differ from the mechanisms of the anti-PF4/heparin immune response seen in OA patients after joint
replacement.
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Background
Heparin-induced thrombocytopenia (HIT) is an immune-
mediated disorder that can develop during anticoagulant
therapy with heparin [1]. HIT is associated with antibodies
(Abs) that recognize the complexes formed between
platelet factor 4 (PF4) and heparin [2]. There is increasing
evidence that immune complexes formed by IgG Abs and
the PF4/heparin complex bind and activate platelets result-
ing in acceleration of the coagulation pathway [3]. Re-
cently, anti-PF4/heparin Abs have also been demonstrated
in individuals who have not received heparin treatment [4].
PF4 could be an antigenic target in autoimmune diseases
[5]. Additionally, anti-PF4/heparin Abs can be induced
in patients who have undergone major surgery, even
without any exposure of unfractionated heparin [6]. The
development of HIT has been associated with postopera-
tive thromboprophylaxis with fondaparinux, a factor Xa
inhibitor [7]. Other examples of so-called “spontaneous”
HIT preceding inflammatory or infectious triggers have
been reported [8]. Krauel et al. [9] proposed that bacterial
infections could trigger anti-PF4/heparin Ab formation.
Anti-PF4/heparin IgG Abs are generated in approximately
20 % of patients undergoing total knee arthroplasty (TKA)
[10]. In addition to the administration of heparin for
anticoagulation during thromboprophylaxis, TKA poses a
substantial challenge to the immune system because of
mechanical damage to articular connective tissue [11].
PF4 is rapidly released after platelet activation and forms
tetramers that bind to polyanions such as heparin, forming
PF4/heparin complexes [12]. The resultant immune com-
plexes induce the immune response resulting in the
production of anti-PF4/heparin Abs [13]. However, the
immunobiology of the anti-PF4/heparin Ab response is not
well understood. Among surgical procedures, joint replace-
ments result in extremely high rates of postoperative anti-
PF4 Abs. The joint replacement procedure itself might be
capable of triggering anti-PF4 Ab formation in both pa-
tients with osteoarthritis (OA) and those with rheumatoid
arthritis (RA), which is an autoimmune disease; however,
the frequency of and risks associated with anti-PF4/heparin
Ab formation in RA patients who undergo joint replace-
ment surgery without heparin exposure remain unclear.
In this study we compared the rate of seroconversion
with anti-PF4/heparin Ab positive status between patients




Between September 2013 and March 2015 a total of 120
patients were enrolled in this randomized controlled trial.
Patients were given edoxaban alone or edoxaban plus a
foot pump as described previously [14]. The primary ef-
fectiveness outcome was total venous thromboembolisms
(VTEs); these included asymptomatic deep vein throm-
boses (DVTs) up to postoperative day (POD) 10, symp-
tomatic DVTs, and fatal/nonfatal pulmonary embolisms
(PEs) up to POD 28. The study protocol was approved
by the ethics committees at the Nagasaki Medical Cen-
ter (Protocol No. 25004), and all patients gave their
written informed consent to participate. This study was
registered in the ISRCTN registry (ISRCTN 18090286).
The Japanese Study of Prevention and Actual Situation
of Venous Thromboembolism after Total Arthroplasty
(J-PSVT) is a hospital-based, prospective cohort study de-
signed to document the effectiveness and safety of current
standard thromboprophylactic agents, including unfractio-
nated heparin (UFH), low-molecular-weight heparin
(LMWH), fondaparinux, and antiplatelet agents, approved
for use in Japan [15]. Data were collected prospectively on
all patients undergoing primary TKA and total hip arthro-
plasty (THA) in 34 NHO hospitals since 2007–2010. The
primary aim of the J-PSVT was to determine the rates of
VTEs and seroconversion rates of anti-PF4/heparin Ab in
patients undergoing TKA and THA, with all patients eval-
uated for the presence of all (symptomatic/nonsympto-
matic) DVTs on POD 10. The trial was registered in the
Japan UMIN Clinical Trial Registry (UMIN000001366).
The study protocol was approved by the ethics commit-
tees of the National Hospital Organization central institu-
tional review board (No 0623004). Written informed
consent was obtained from each individual for their clin-
ical records to be used in this study.
Blood sampling
Serum samples were obtained before surgery and at POD
10 and were stored at −30 °C. An enzyme-linked immuno-
sorbent assay (ELISA) kit (GTI Diagnostics, Waukesha, WI,
USA) was used to measure the IgG-class anti-PF4/heparin
Ab (HIT Ab) according to the manufacturer’s instructions.
ELISA reactivity (optical density (OD)) was expressed rela-
tive to a standard control. The cutoff value was set at 0.50
OD. We defined seroconversion as a negative ELISA result
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before surgery followed by a positive result on POD 10 with
a 2-fold or more increase in OD, as defined in a previous
study [14]. HIT is characterized by a decrease in the platelet
count 50 % beginning 5–10 days after the start of heparin
or major surgery in association with the appearance of
platelet-activating anti-PF4/heparin Ab [16]. We therefore
analyzed the anti-PF4/heparin Ab at POD 10.
In J-PSVT, anti-PF4/heparin Abs were evaluated using
a commercially available ELISA for detecting IgG, IgA,
and IgM (HPIA; Diagnostica Stago, Asnières-sur-Seine,
France) at a central laboratory by personnel blinded to
all clinical information. The cutoff value was approxi-
mately 0.4–0.5 OD units, depending on the assay kit.
Each kit has a specific reference standard to determine
the cutoff value. We defined seroconversion as a positive
test result on POD 10 corresponding to a negative result
before surgery. In addition, we considered patients who
tested positive before surgery to be seroconverters if
their blood sample on POD 10 was positive with a 2-fold
or higher increase in OD.
Immunoblot analysis
Serum samples (8 μl) were diluted 10-fold with phosphate-
buffered saline (PBS) and incubated with protein G-
Sepharose-4B beads or heparin-Sepharose-4B beads
(Invitrogen Carlsbad, CA, USA) for 30 min with gentle
mixing. The beads were washed with PBS three times
and eluted with 20 μl of lithium dodecyl sulfate (LDS)
sample buffer at 70 °C for 10 min. The eluted protein
fractions were then separated under reducing conditions
by NuPAGE 3–8 % Tris-acetate gel electrophoresis
(Invitrogen). Proteins were electrophoretically transferred
onto an Invitrogen polyvinylidene fluoride membrane and
incubated overnight at 4 °C with blocking solution (5 %
nonfat milk in Tris-buffered saline with 0.05 % Tween 20
(TTBS)). The blocked membrane was incubated with rabbit
anti-human PF4 polyclonal antibody (Abcam, Cambridge,
UK; 1:10,000 dilution with 1 % nonfat milk in TTBS)
for 1 h at room temperature and then washed five times
with TTBS buffer for 10 min each time at room
temperature with constant shaking. The membrane was
then incubated with horseradish peroxidase-conjugated
second antibody (1:3,000 dilution; Santa Cruz Biotech-
nology) for 1 h at room temperature and washed five
times with TTBS buffer for 10 min each time at room
temperature with constant shaking. Immunodetection
was performed using an enhanced chemiluminescence
western blotting kit (Amersham, Little Chalfont, UK).
Table 1 Baseline characteristics of RA and OA patients
Total subjects RA patients OA patients
(n = 124) (n = 26) (n = 98) p value
Gender (male/female) 20/104 2/24 18/80 0.188
Age (years)
Mean ± SD 73.4 ± 6.9 69.8 ± 8.5 74.3 ± 6.1 0.021
Range 54–85 54–80 54–85
BMI (kg/m2)
Mean ± SD 26.7 ± 4.2 25.7 ± 4.7 26.9 ± 4.0 0.150
History of venous thrombosis, n (%) 7 (5.7 %) 3 (11.5 %) 4 (4.1 %) 0.143
Comorbidities
Hypertension 86 (69.4 %) 20 (76.9 %) 66 (67.4 %) 0.346
Ischemic heart disease 6 (4.8 %) 0 6 (6.1 %) 0.196
Diabetes 29 (23.4 %) 7 (26.9 %) 22 (22.4 %) 0.632
Cerebrovascular disease 10 (8.1 %) 2 (7.7 %) 8 (8.2 %) 0.938
Operation time (min)
Mean ± SD 93.7 ± 23.0 93.8 ± 21.1 93.6 ± 23.5 0.711
General anesthesia, n (%) 124 (100 %) 26 (100 %) 98 (100 %)
Use of elastic stocking, n (%) 124 (100 %) 26 (100 %) 98 (100 %)
Use of tourniquet, n (%) 124 (100 %) 26 (100 %) 98 (100 %)
Use of cement, n (%) 124 (100 %) 26 (100 %) 98 (100 %)
Prophylaxis
Edoxaban (mg/day) 21.2 ± 7.4 21.3 ± 7.6 21.1 ± 7.4 0.891
(duration) (11.4 ± 1.8 days) (12.0 ± 0.6 days) (11.3 ± 2.0 days) 0.155
BMI body mass index, OA osteoarthritis, RA rheumatoid arthritis
Izumi et al. Arthritis Research & Therapy  (2016) 18:191 Page 3 of 10
Sera from 13 healthy subjects (six males, seven females;
mean age of 42.7 ± 12.7 years) were used as controls.
Measurement of serum PF4
Serum PF4 concentrations were assayed using an ELISA
kit from R&D Systems (Minneapolis, MN, USA) accord-
ing to the manufacturer’s instructions.
Statistical analysis
The significance of differences in discrete and continu-
ous variables was assessed using chi-square and Mann–
Whitney tests, respectively. Multivariate logistic regres-
sion was performed to identify independent risk factors
for anti-PF4/heparin Ab seroconversion. Variables with
p < 0.25 by chi-square test or Fisher’s exact test in the
univariate logistic regression analysis were selected for
the multivariate model. The Wilcoxon signed rank test
was used for the comparison of a pair of samples. All
data processing and analyses were performed using the
Statistical Analysis System (SAS) and SPSS version 18
(SPSS, Chicago, IL, USA).
Results
Patient demographic data
The characteristics of the total study population that
underwent TKA are presented in Table 1.
Table 2 Baseline characteristics of patients with high titers of
anti-PF4/heparin antibody
Postoperative seroconversion (OD≥ 0.4)
Positive Negative
(n = 28) (n = 96) p value
Gender(male/female) 6/22 14/82 0.275
Age (years), mean ± SD 73.8 ± 6.6 73.3 ± 7.0 0.551
BMI (kg/m2), mean ± SD 27.3 ± 3.9 26.5 ± 4.2 0.532
History of venous thrombosis, n (%) 1 (3.6 %) 6 (6.3 %) 0.503
Comorbidities, n (%)
Hypertension 18 (64.3 %) 65 (67.7 %) 0.735
Ischemic heart disease 2 (7.1 %) 4 (4.2 %) 0.409
Diabetes 9 (32.1 %) 18 (18.8 %) 0.131
Cerebrovascular disease 3 (10.7 %) 7 (7.3 %) 0.401
Operation time (min), mean ± SD 91.1 ± 20.6 94.3 ± 23.7 0.682
RA/OA 3/25 23/73 0.130
Foot pump, n (%) 12 (42.9 %) 47 (49.0 %) 0.569
Use of steroid, n (%) 2 (7.1 %) 16 (16.7 %) 0.171
Use of MTX, n (%) 1(3.6 %) 9 (9.4 %) 0.292
BMI body mass index, OA osteoarthritis, OD optical density, RA rheumatoid
arthritis, MTX methotrexate, PF4 platelet factor 4
Fig. 1 Preoperative (before) and POD 10 (after) OD levels and seroconversion rates of anti-PF4/heparin antibodies in RA patients with or without
anti-CCP Ab and in OA patients. Wilcoxon signed rank test was used for the comparison of a pair of samples. One RA patient who tested positive
before surgery (dots in parentheses) did not meet the definition of seroconversion and was excluded from the analysis. CCP citrullinated peptide,
ELISA enzyme-linked immunosorbent assay, OA osteoarthritis, OD optical density, RA rheumatoid arthritis
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The mean age at the time of TKA was 71.0 years in
the RA group and 74.3 years in the OA group. Other
demographic differences between RA patients and OA
patients did not reach statistical significance (Table 1).
All RA patients fulfilled the 1987 American College of
Rheumatology criteria for diagnosis of RA [17]. The
mean disease duration was 13.3 ± 8.2 years. Twenty pa-
tients were classified in Steinbroker’s stage III and six
patients in stage IV, and eight patients were classified in
functional Class 2 and 18 patients in Class 3. Among 26
patients, 18 patients (69.2 %) were positive for anticitrul-
linated peptide antibody (anti-CCP Ab) and 15 patients
(57.7 %) were positive for rheumatoid factor (RF).
Among 23 patients with RA, 18 patients were treated
with prednisolone (mean dose 5.0 ± 2.7 mg/day) and 10
patients were treated with methotrexate (MTX; mean
dose 6.6 ± 2.8 mg/week) at the time of blood sampling.
Risk factors for anti-PF4/heparin IgG antibody
seroconversion
Univariate analysis did not identify the variables that dif-
fered significantly between patients who did or did not
become seropositive for the anti-PF4/heparin Ab post-
operatively (Table 2). Next we compared the OD values
for anti-PF4/heparin IgG during the preoperative and
postoperative periods (Fig. 1). The seroconversion rates
of anti-PF4/heparin Ab were significantly lower in RA
patients than in OA patients who received TKA (4.5 % vs
25.8 %, p = 0.021). There was no significant difference in
the anti-PF4/heparin IgG OD values before surgery and at
POD 10 in RA patients with anti-CCP Ab. However, the
anti-PF4/heparin IgG OD values significantly differed be-
tween the preoperative and postoperative measurements
in OA patients (Fig. 1). Although there is no statistical sig-
nificance, the titers of RF were lower in RA patients with
seroconverted postoperative anti-PF4/heparin compared
with those without postoperative ant-PF4/heparin Ab
(Table 3). The titers of anti-CCP Ab, however, were signifi-
cantly lower in RA patients with postoperative ant-PF4/
heparin Ab compared with those without postoperative
ant-PF4/heparin Ab (Table 3).
Comparison of anti-PF4/heparin antibody seroconversion
rates between patients with RA and OA using the J-PSVT
database
To further explore the role of primary diseases in anti-
PF4/heparin Ab formation, we compared the serocon-
version rates between patients with RA and with OA
Table 3 Baseline characteristics of patients with high titers (OD ≥ 0.40) of anti-PF4/heparin antibody
Rheumatoid arthritis Osteoarthritis
Postoperative seroconversion (OD≥ 0.4) Postoperative seroconversion (OD≥ 0.4)
Positive Negative Positive Negative
(n = 3) (n = 23) p value (n = 25) (n = 73) p value
Gender (male/female) 0/3 2/21 0.5950 6/19 12/61 0.286
Age (years), mean ± SD 67.7 ± 9.5 70.0 ± 805 0.6289 74.6 ± 6.1 74.3 ± 6.1 0.598
Disease duration (years) 14.0 ± 10.1 13.2 ± 8.2 0.7734
BMI (kg/m2)
Mean ± SD 25.2 ± 1.0 25.8 ± 5.0 0.9360 27.5 ± 4.0 26.7 ± 4.0 0.628
History of venous thrombosis, n (%) 1 (33.3 %) 2 (8.7 %) 0.2090 0 4 (5.5 %) 0.301
Comorbidities
Hypertension 2 (66.7 %) 18 (78.3 %) 0.6539 17 (68.0 %) 49 (67.1 %) 0.936
Ischemic heart disease 0 0 2 (8.0 %) 4 (5.5 %) 0.482
Diabetes 1 (33.3 %) 6 (26.1 %) 0.7901 8 (32.0 %) 14 (19.2 %) 0.185
Cerebrovascular disease 1 (33.3 %) 1 (4.3 %) 0.0764 2 (8.0 %) 6 (8.2 %) 0.669
Operation time (min)
Mean ± SD 88.0 ± 4.4 94.6 ± 22.4 0.8096 91.4 ± 21.8 94.4 ± 24.2 0.699
RF (titer IU/ml) 1/3 (17.3 ± 24.8) 14/23 (59.8 ± 73.7) 0.5558 0.1366 N/a N/a
Anti-CCP Ab (titer U/ml) 0/3 (0.6 ± 0.0) 18/23 (246.2 ± 560.1) 0.0215 0.0209 N/a N/a
CRP (mg/dl) 1.51 ± 1.09 1.24 ± 1.37 0.3086 N/a N/a
Use of steroid 2 (66.7 %) 16 (69.6 %) 0.9185 N/a N/a
Use of MTX 1 (33.3 %) 9 (39.1 %) 0.8461 N/a N/a
Foot pump 2 (66.7 %) 11 (47.8 %) 0.5393 10 (40.0 %) 36 (49.3 %) 0.421
anti-CCP Ab anti-citrullinated peptide antibody, BMI body mass index, CRP C-reactive protein, MTX methotrexate, N/a not applicable, OD optical density,
PF4 platelet factor 4, RF rheumatoid factor
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under various thromboprophylaxis protocols using the J-
PSVT database (Fig. 2). Similar trends were observed for
patients receiving LMWH or UFH; however, we were
unable to demonstrate a statistically significant differ-
ence in the seroconversion rates of anti-PF4/heparin Ab
between RA patients and OA patients receiving these
therapies. The seroconversion rates of anti-PF4/heparin
Ab, however, were significantly lower in RA patients
than in OA patients who received fondaparinux. These
findings are consistent with the present RCT study dem-
onstrating that RA protects against anti-PF4/heparin Ab
formation under thromboprophylaxis using a similar
factor Xa inhibitor, edoxaban. We also analyzed the
relationship between the seroconverting of anti-PF4/
heparin Ab and the occurrence of DVT or bleeding
in RA patients using this large J-PSVT database. The
seroconversion of anti-PF4/heparin Ab did not affect
the occurrences of postoperative DVT (anti-PF4/heparin
Ab +21.1 % vs anti-PF4/heparin Ab –23.6 %) or bleeding
(anti-PF4/heparin Ab +5.3 % vs anti-PF4/heparin Ab –
5.6 %) in RA patients.
Binding affinity of PF4 for heparin in RA patients and OA
patients
We measured preoperative PF4 using the ELISA method.
There was no significant difference in preoperative PF4
levels between RA patients and OA patients (Fig. 3). PF4
has been shown to bind to heparin and we hypothesized
that the ability of circulating PF4 to bind heparin may
differ between RA patients and OA patients. To test this,
we compared the heparin-binding affinity of PF4 in RA
patients and OA patients using serum samples collected
prior to surgery. We used heparin-Sepharose beads to
isolate PF4 with heparin-binding ability from the serum.
Samples of serum from RA patients or OA patients
were incubated with heparin-Sepharose beads and gently
mixed. The beads were then washed and the heparin-
bound materials were eluted and subjected to anti-PF4
Fig. 2 Anti-PF4/heparin seroconversion rates and proportion of patients who tested strongly positive in patients who underwent TKA. Seroconversion
rate and the proportion of patients who tested positive (ELISA values ≥ 0.4 optical density (OD) units) were calculated for patients receiving
unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), fondaparinux, or only mechanical thromboprophylaxis (no anticoagulant)
after TKA. Each group was divided into two subgroups based on the primary diseases (RA or OA). The seroconversion rates were compared
between the RA patients or OA patients in each group using the chi-square test. When the sample size of a cell in a 2 × 2 table was less than
10, Fisher’s exact test was used instead. p values were not corrected for multiple hypothesis tests. ELISA enzyme-linked immunosorbent assay,
OA osteoarthritis, RA rheumatoid arthritis
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immunoblot analysis. As shown in Fig. 4a, the bands
representing heparin-bound PF4 did not differ between
RA patients and OA patients, suggesting that circulat-
ing PF4 had similar heparin-binding affinity in both
RA patients and OA patients.
Circulating IgG bound to PF4 between RA patients and
OA patients
Next we examined the circulating IgG bound to PF4
using sera from RA patients and OA patients. Serum
samples were incubated with protein-G-sepharose beads
and IgG fractions were eluted with LDS sample buffer
and subjected to anti-PF4 immunoblot analysis. As
shown in Fig. 4b, c, the IgG fractions isolated from
healthy subjects or OA patients barely showed a PF4
band. In contrast, PF4 bands were clearly demonstrated
from the IgG fractions isolated from RA patients; this
suggests that the circulating IgG was bound to PF4 in
RA patients. Using the sera from all RA patients (n = 26)
and OA patients (n = 97), we performed the same analysis
(Table 4). The PF4 bands were more frequently observed
in RA patients than in OA patients (RA 18/26, 69.2 % vs
OA 10/98, 10.2 %, p = 0.0001). In RA patients, the use of
prednisolone or methotrexate did not associate with the
detection of PF4 in the IgG fractions (data not shown).
These results suggest that circulating IgG bound to PF4 or
formed immune complexes with PF4 in the majority of
RA patients.
Discussion
In this study we examined the differences in the rates of
seroconversion to anti-PF4/heparin Ab positive status
between patients with OA and with RA who underwent
TKA. Previous studies have characterized the presence
of anti-PF4/heparin Ab in patients with systemic lupus
erythematosus (SLE) or anti-phospholipid Ab syndrome
[5, 18]. Anti-PF4/heparin Abs have been reported to
occur significantly more often in SLE patients than in
healthy subjects [5]. However, the prevalence of anti-PF4/
heparin Abs has not been investigated in other rheumatic
diseases, including RA. To our knowledge, this is the first
report documenting the frequency of seroconversion to
anti-PF4/heparin Ab positive status after major joint sur-
gery in RA patients. The most significant finding of this
study was that TKA can induce seroconversion to anti-
PF/heparin Ab positive status without exposure to hep-
arin; however, in RA patients the induction of anti-PF4/
heparin Ab production occurred less frequently than in
OA patients. Of the OA patients who underwent TKA,
25.8 % became seropositive for anti-PF4/heparin Ab.
These findings are consistent with the findings of previous
studies, in which the seroconversion rates in similar pa-
tient populations that were not exposed to heparin were
reported to be 14–24 % [6]. However, a significantly lower
percentage of RA patients became seropositive for anti-
PF4/heparin Abs after TKA than OA patients (4.5 % vs
25.8 %) in our study.
It is generally accepted that HIT is caused by anti-
bodies which recognize complexes of PF4 and heparin
[2]. The PF4 tetramer binds to heparin and glycosamino-
glycans, an interaction that is central to the pathogenesis
of HIT [19]. It has also been demonstrated that the
binding of PF4 to certain bacteria or nucleic acids can
initiate the generation of HIT-like Abs [20, 21]. Heparin
has high avidity for PF4, and thus provides antigenic
stimulation for HIT Abs [21]; however, a substantial
number of patients who undergo major orthopedic
surgery subsequently produce anti-PF4/heparin Abs with-
out exposure to heparin. Perioperative inflammatory stim-
uli seem to disrupt PF4/heparin-specific B-cell tolerance
[22]. In addition to the presence of heparin, the formation
of immunogenic complexes that provoke HIT Abs de-
pends on the availability of PF4. Upon release from acti-
vated platelets, PF4 rapidly associates with heparin sulfate
in endothelial cells and can be brought back into circula-
tion [23]. The availability of PF4 is therefore influenced by
acute platelet activation, and logically plays a role in the
risk for generation of PF4/heparin Abs during major joint
Fig. 3 Preoperative serum levels of PF4 in RA patients and OA
patients. Preoperative serum levels of PF4 were determined by ELISA
in RA patients and OA patients. Results expressed as the mean ±
standard deviation. There was no significant difference in serum
levels of PF4 between RA patients and OA patients. OA osteoarthritis,
RA rheumatoid arthritis
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surgery. However, preoperative serum PF4 levels did not
differ between patients with RA and with OA.
PF4 binds to heparin-like molecules and PF4/heparin
complexes stimulate anti-PF4/heparin Abs [24]. Thus,
we reasoned that the increase in anti-PF4/heparin Abs
after TKA might be part of the immune activation that
occurs during postoperative inflammatory processes. In
support of this hypothesis, we observed the appearance
of anti-PF4/heparin Abs during the postoperative period
after arthroplasty. However, the B-cell-mediated immune
responses to PF4/heparin in RA patients were shown to
be lower compared with those in OA patients. Assuming
a causal relationship, we hypothesized that prescribed
immunosuppressive medications, such as steroids or
methotrexate, might reduce the likelihood of serocon-
version to anti-PF4/heparin Ab positive status in RA
patients. However, our results indicate that these
medications did not affect anti-PF4/heparin Ab induction.
Additionally, our data suggest that the heparin-binding
affinity of circulating PF4 was not different between RA
patients and OA patients.
More recently, Ohyama et al. [25] demonstrated that
immune complexes containing PF4 are present specific-
ally in the sera of RA patients, and these immune com-
plexes could be a biomarker for the diagnosis of RA.
These findings suggest that circulating PF4 is bound to
IgG in established RA patients, which may contribute
to the reduced likelihood of anti-PF4/heparin Abs in
these patients. Although there is no statistical signifi-
cance, the titers of RF were lower in RA patients with
postoperative ant-PF4/heparin Ab compared with those
without postoperative ant-PF4/heparin Ab. Further-
more, titers of anti-CCP Ab were significantly lower in
RA patients with postoperative ant-PF4/heparin Ab
compared with those without postoperative ant-PF4/
Fig. 4 a Anti-PF4 immunoblot analysis using the heparin-binding fractions isolated from RA or OA patient sera. Heparin-binding fractions isolated
from RA and OA patient sera using heparin-Sepharose-4B beads were subjected to anti-PF4 immunoblot analysis. PF4 bands (MW = 7800) were
detected in the heparin-binding fractions from RA patients or OA patients under reducing conditions. A representative result of three independent
experiments. b, c Anti-PF4 immunoblot analysis using the IgG fractions from healthy subjects (b) or RA and OA patient sera (c) using
protein G sepharose-4B beads were subjected to anti-PF4 immunoblot analysis. PF4 bands (MW = 7800) were detected in the IgG fractions
from RA patients under reducing conditions. Additional brood bands observed under reducing conditions are light chains generated from cleavage of
the thiol-disulfide bridge of immunoglobulins. In Fig. 3c, among four patients, anti-CCP Ab plus RF were detected in two patients (RA2 and
RA4). A representative result of three independent experiments. OA osteoarthritis, RA rheumatoid arthritis
Table 4 Number of patients carrying IgG-associated PF4
RA OA Healthy controls
(n = 26) (n = 98) (n = 13)
18/26 (69.2 %) 10/98 (10.2 %) 0/13 (0 %)
PF4 platelet factor 4, RA rheumatoid arthritis, OA osteoarthritis
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heparin Ab. Immune complexes containing PF4 were
found in the serum of 52 % of RA patients with anti-CCP
Ab [26, 27]. It is possible that RA patients with high titers
of RF or anti-CCP Ab could be preimmunized with PF4
which may be related to the abortive induction of anti-
PF4/heparin Ab [27]. Our findings indicate that the circu-
lating PF4 isolated from RA patients had a greater ability
to bind IgG than the circulating PF4 in OA patients,
which suggests preexisting immune responses against PF4
during the chronic immune-mediated inflammatory
processes of RA. These responses may interfere with
anti-PF4/heparin plasma cell differentiation through
either regulatory or immune-tolerance mechanisms.
The affinity of circulating PF4 for IgG in RA patients
suggests that the immature B-cell immune response
against PF4 occurs more frequently in RA patients
than in OA patients. Our results suggest that certain
immune reactions against PF4 are preexisting in RA pa-
tients. These preexisting immune responses may explain
the reduced postoperative production of anti-PF4/heparin
Abs in RA patients. Previous studies have demonstrated
that an encounter between an immature B cell and its
cognate antigen can lead to B-cell anergy [28]. This sug-
gests a possible mechanism of B-cell tolerance for PF4/
heparin complexes in patients with chronic inflammatory
disorders such as RA. A recent study of anti-PF4/ heparin
immunization in patients after cardiac surgery suggested
that perioperative inflammation affects the immune re-
sponse [29]. Alternatively, chronic rheumatoid inflamma-
tion may downregulate these perioperative inflammations
that contribute to occurrence of anti-PF4/ heparin Ab in
RA patients.
This study had several limitations. One major limita-
tion was the potential for several biases in this quasi-
randomized controlled trial. We were not able to obtain
sufficient numbers of patients (particularly RA patients)
to achieve good statistical power, so there is the un-
deniable possibility that the study may have been under-
powered. Also, the J-PSVT does not provide information
related to the RA severity score or data regarding treat-
ments, such as antirheumatic drugs and glucocorticos-
teroids, so we were not able to adjust for these in our
statistical models.
Conclusions
This study revealed a lower rate of seroconversion to
anti-PF4/heparin IgG positive status after TKA in RA
patients than in OA patients. This suggests that the
autoimmune-like features of anti-PF4/heparin Ab pro-
duction cannot be explained by the postoperative in-
duction of this antibody. Our data provide further
evidence for the unique profile of anti-PF4/heparin Ab in-
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